A pan-cancer analysis of 2,930 patients across 11 tumor types found that ALK mutation was associated with significantly ...
Researchers at the University of Oregon have developed an artificial intelligence tool that can read genetic code the way ...
Researchers at the University of Cincinnati Gardner Neuroscience Institute's Brain Tumor Center have been confirmed as the ...
After a cancer diagnosis, patients often have many questions, not only about their treatment but also about what the ...
Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...
Desai, MBBS, MD, assistant professor of thoracic medical oncology/head and neck medical oncology at Fox Chase Cancer Center ...
Millions of tons of plastic waste accumulate in landfills and oceans every year. One promising response is to engineer ...
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of ...
Pfizer and Arvinas' Veppanu Gets FDA OK Alongside Guardant Health CDx for ESR1-Mutated Breast Cancer
The agency's decision was based on data from the VERITAC-2 trial, which showed Veppanu improved progression-free survival by nearly three months over fulvestrant.
Members of the FDA’s Oncologic Drugs Advisory Committee questioned AstraZeneca’s trial design of switching treatments earlier ...
When comprehensive tissue next-generation sequencing (NGS) fails, liquid biopsy should be the reflex strategy, especially in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results